Latest Conference Coverage


Risk of ARIA-E in Donanemab Attenuated Through New Enhanced Titration Method of Delivery

Risk of ARIA-E in Donanemab Attenuated Through New Enhanced Titration Method of Delivery

October 30th 2024

Compared with the standard dosing arm, those on an enhanced titration dosing of donanemab demonstrated a 41% reduction in the relative risk of ARIA-E.


Anti-Tau Agent E2814 Shows Impact on Early and Late Tau Biomarkers, Further Supporting Development

Anti-Tau Agent E2814 Shows Impact on Early and Late Tau Biomarkers, Further Supporting Development

October 29th 2024

Despite a small cohort sample size, treated patients with E2814 demonstrated significant reductions in p-tau217 after 12 weeks of treatment, sustained through the 108-week time point.


Paul Melmeyer, MPP (Credit: CGTLive)

The Significance of Gene Therapy in Neuromuscular Medicine at the 2025 MDA Conference: Paul Melmeyer, MPP

October 28th 2024

Prior to the 2025 MDA Conference, the vice president of Public Policy & Advocacy at the Muscular Dystrophy Association talked about the increasing interest in gene therapy in the field of neuromuscular diseases.


Investigational Nipocalimab Demonstrates Efficacy and Safety in Adolescent Population of Myasthenia Gravis

Investigational Nipocalimab Demonstrates Efficacy and Safety in Adolescent Population of Myasthenia Gravis

October 26th 2024

In a small sample population of adolescents with myasthenia gravis, nipocalimab met its primary end point, showing a significant reduction in total serum immunoglobuin over a 24-week period.


Future Plans and Clinical Promise of Inebilizumab in Myasthenia Gravis: Richard Nowak, MD, MS

Future Plans and Clinical Promise of Inebilizumab in Myasthenia Gravis: Richard Nowak, MD, MS

October 25th 2024

The director of the myasthenia gravis clinic at Yale University provided additional insight on the MINT study of inebilizumab in myasthenia gravis, some of the subanalyses within, and next plans in the drug’s development. [WATCH TIME: 5 minutes]


Robert J. Fox, MD; Andreas Muehler, MD, MBA

How Vidofludimus Calcium Addresses Unmet Treatment Needs in Multiple Sclerosis: Andreas Muehler, MD, MBA

October 25th 2024

The chief medical officer at Immunic provided clinical insight on the dual mechanism of action of vidofludimus calcium, and how its positioned as a treatment option across all MS subtypes. [WATCH TIME: 3 minutes]


The Potential of Device-Assisted Therapies in PD: Insights From the Phase 1/2 DIVE-I Trial

The Potential of Device-Assisted Therapies in PD: Insights From the Phase 1/2 DIVE-I Trial

October 25th 2024

David Devos, MD, PhD, a neuropharmacologist at the University of Lille, in France, discussed positive data from an early-stage study assessing InBrain Pharma’s device-assisted therapy in Parkinson disease.


Lawrence Robinson, MD

Challenges and Opportunities of Adapting Medical Education in a Digital Age: Lawrence Robinson, MD

October 24th 2024

The senior scientist at Sunnybrook Research Institute talked about both the opportunities and challenges with the shift of technological advancement in medical education, especially in fostering critical thinking and managing the vast influx of information. [WATCH TIME: 4 minutes]


NeuroVoices: Lawrence Robinson, MD, on Innovating Educational Approaches for Neuromuscular Specialists

NeuroVoices: Lawrence Robinson, MD, on Innovating Educational Approaches for Neuromuscular Specialists

October 23rd 2024

The senior scientist at Sunnybrook Research Institute in Toronto, Ontario, provided clinical insight on his lecture given at AANEM 2024, focusing on the challenges and opportunities of teaching the next generation of practitioners.


Revised McDonald Diagnostic Criteria Signals New Era in Multiple Sclerosis Treatment

Revised McDonald Diagnostic Criteria Signals New Era in Multiple Sclerosis Treatment

October 22nd 2024

The 2024 revisions to the McDonald diagnostic criteria for multiple sclerosis (MS) mark a significant advancement in the early detection and diagnosis of the disease, with new biomarkers and a broadened scope that may lead to earlier intervention and improved patient outcomes.


Understanding Nipocalimab’s Impact on Myasthenia Gravis Using MG-ADL

Understanding Nipocalimab’s Impact on Myasthenia Gravis Using MG-ADL

October 22nd 2024

Constantine Farmakidis, MD, an associate professor of neurology at the University of Kansas Medical Center, provided clinical commentary on a subanalysis of a phase 3 study assessing nipocalimab, an investigational agent, in generalized myasthenia gravis.


Details Behind the Phase 3 MyClad Study of Cladribine in Myasthenia Gravis

Details Behind the Phase 3 MyClad Study of Cladribine in Myasthenia Gravis

October 22nd 2024

Study investigator Henry Kaminski, MD, provided clinical insight on a unique trial assessing the efficacy and safety of oral cladribine tablets, an FDA-approved medication for multiple sclerosis, in patients with myasthenia gravis.


Luc Truyen, MD, PhD  (Credit: Argenx)

Subcutaneous Efgartigimod PH20 Efficacious in Patients With CIDP Previously Treated

October 20th 2024

A recent analysis of the phase 3 ADHERE trial demonstrated the clinical benefit of subcutaneous efgartigimod PH20 in patients with chronic inflammatory demyelinating polyneuropathy.


Clinical Insights From Phase 3 VIVACITY-MG3 Study of Nipocalimab in Generalized Myasthenia Gravis

Clinical Insights From Phase 3 VIVACITY-MG3 Study of Nipocalimab in Generalized Myasthenia Gravis

October 19th 2024

Tuan Vu, MD, a professor of neurology at the University of South Florida, provided brief commentary on topline data of the phase 3 VIVACITY-MG3 study presented at AANEM 2024.


Phase 3 Trial to Assess Therapeutic Effect of IV Efgartigimod in Seronegative Myasthenia Gravis

Phase 3 Trial to Assess Therapeutic Effect of IV Efgartigimod in Seronegative Myasthenia Gravis

October 19th 2024

The phase 3 study is expected to include 110 patients with seronegative myasthenia gravis who will be randomly assigned to IV efgartigimod or placebo for a 5-week follow-up, followed by an open-label extension.


Therapeutic Potential of Self-Administered Subcutaneous Rozanolixizumab in Myasthenia Gravis: Rachana K. Gandhi Mehta, MBBS

Therapeutic Potential of Self-Administered Subcutaneous Rozanolixizumab in Myasthenia Gravis: Rachana K. Gandhi Mehta, MBBS

October 18th 2024

The assistant professor of neurology at Wake Forest School of Medicine provided clinical insight on MG0020, a phase 3 trial assessing a self-administration of rozanolixizumab through a syringe driver. [WATCH TIME: 3 minu]


Ranging Cycle Cadence of Rozanolixizumab Highlights Need for Individualized Treatment Approach

Ranging Cycle Cadence of Rozanolixizumab Highlights Need for Individualized Treatment Approach

October 18th 2024

Despite balanced baseline characteristics, patients ranged from low to high number of rozanolixizumab treatment cycles, suggesting the need for a personalized approach.


Episode 126: Exploring the Therapeutic Potential of ATH434 in Multiple System Atrophy

Episode 126: Exploring the Therapeutic Potential of ATH434 in Multiple System Atrophy

October 18th 2024

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Daniel Claassen, MD, MS. [LISTEN TIME: 14 minutes]


Ali A. Habib, MD  (Credit: UCI School of Medicine)

Phase 3b ADAPT NXT Study Confirms Efficacy of Cyclic and Biweekly Dosing of Efgartigimod in Generalized Myasthenia Gravis

October 17th 2024

Findings showed that both fixed cycles and every-other-week dosing regimens of efgartigimod were well tolerated and effective in improving clinical outcomes in patients with generalized myasthenia gravis.


Phase 3 PREVAIL Study to Test Bispecific Nanoantibody Gefurulimab in Generalized Myasthenia Gravis

Phase 3 PREVAIL Study to Test Bispecific Nanoantibody Gefurulimab in Generalized Myasthenia Gravis

October 17th 2024

The PREVAIL trial, presented at the 2024 AANEM meeting, is investigating gefurulimab, a bispecific nanoantibody designed to inhibit complement activation, as a potential treatment for patients with generalized myasthenia gravis.


Therapeutic Benefits of Steroid-Sparing Effect From New Myasthenia Gravis Medications: Christopher Scheiner, MD, PhD

Therapeutic Benefits of Steroid-Sparing Effect From New Myasthenia Gravis Medications: Christopher Scheiner, MD, PhD

October 17th 2024

The neuromuscular specialist at the University of Tennessee Medical Center provided clinical insight on a retrospective analysis studying the long-term corticosteroid patterns of approved treatments for generalized myasthenia gravis. [WATCH TIME: 5 minutes]


Tuan Vu, MD  (Credit: LinkedIn)

Rozanolixizumab Efficacious in Older Patients With Generalized Myasthenia Gravis, Phase 3 Data Show

October 17th 2024

Rozanolixizumab demonstrated efficacy in patients with generalized myasthenia gravis aged at least 65 years, despite a higher incidence of comorbidities observed in this population.


Innovative MyClad Study Testing Cladribine Capsules in Generalized Myasthenia Gravis: Henry Kaminski, MD

Innovative MyClad Study Testing Cladribine Capsules in Generalized Myasthenia Gravis: Henry Kaminski, MD

October 16th 2024

The Meta A. Neumann Professor of Neurology at George Washington University provided an overview of a new phase 3 study testing the efficacy and safety of cladribine versus placebo in generalized myasthenia gravis. [WATCH TIME: 3 minutes]


Phase 3 NIMBLE Trial to Test Effects of Pozelimab and Cemdisiran in Myasthenia Gravis

Phase 3 NIMBLE Trial to Test Effects of Pozelimab and Cemdisiran in Myasthenia Gravis

October 16th 2024

Pozelimab and cemdisiran work together to block the complement pathway, which plays a key role in gMG, using two different approaches—one suppresses liver production of a key protein, while the other targets it directly with antibodies.


Complement Inhibition of Zilucoplan Unaffected When Used Concomitantly With IVIg, Plasma Exchange

Complement Inhibition of Zilucoplan Unaffected When Used Concomitantly With IVIg, Plasma Exchange

October 16th 2024

Zilucoplan, approved for generalized myasthenia gravis in 2023, showed consistent complement inhibition, even with additional treatments like IVIg or plasma exchange.


Understanding the Therapeutic Potential of Inebilizumab in Myasthenia Gravis: Richard Nowak, MD, MS

Understanding the Therapeutic Potential of Inebilizumab in Myasthenia Gravis: Richard Nowak, MD, MS

October 16th 2024

The director of the myasthenia gravis clinic at Yale University provided clinical insight on promising phase 3 data assessing inebilizumab, an FDA-approved therapy for NMOSD, in patients with myasthenia gravis. [WATCH TIME: 4 minutes]


Sarosh Ahmed, PT, DPT, CBIS-T  (Credit: X)

Meta-Analysis Reveals Significant Burden of Cardiovascular Comorbidities in Myasthenia Gravis

October 15th 2024

Using data from observational studies, a recent meta-analysis offered a comprehensive overview of the risk profile of cardiovascular comorbidities in patients with myasthenia gravis.

© 2025 MJH Life Sciences

All rights reserved.